Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Niamh ColemanBettzy StephenSiqing FuDaniel KarpVivek SubbiahJordi Rodon AhnertSarina A Piha-PaulJohn WrightSenait N FessahayeFengying OuyangBulent YilmazFunda Meric-BernstamAung NaingPublished in: Cancer medicine (2024)
The combination of sapanisertib and ziv-aflibercept was generally tolerable and demonstrated anti-tumor activity in heavily pre-treated patients with advanced malignancies.